Atossa Therapeutics Inc. [NASDAQ: ATOS] jumped around 0.38 points on Friday, while shares priced at $2.74 at the close of the session, up 16.10%. The company report on April 30, 2021 that Atossa Therapeutics CEO Dr. Steven Quay to Participate in Panel Discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021.
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, announced that Atossa CEO Dr. Steven Quay will participate in a panel discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021 at 10:00 AM ET. The conference will be conducted from May 4-6, 2021.
The panel is titled, “Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!” and also features speakers from multiple well-known venture investment funds. For those interested in attending the conference, registration can be found here.
Atossa Therapeutics Inc. stock is now 188.42% up from its year-to-date (YTD) trading value. ATOS Stock saw the intraday high of $2.80 and lowest of $2.3166 per share. The company’s 52-week high price is 5.08, which means current price is +213.14% above from all time high which was touched on 02/04/21.
Compared to the average trading volume of 11.64M shares, ATOS reached a trading volume of 18448994 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atossa Therapeutics Inc. [ATOS]?
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.26 The Price to Book ratio for the last quarter was 1.72, with the Price to Cash per share for the same quarter was set at 0.33.
How has ATOS stock performed recently?
Atossa Therapeutics Inc. [ATOS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.60. With this latest performance, ATOS shares gained by 33.01% in over the last four-week period, additionally plugging by 77.92% over the last 6 months – not to mention a rise of 65.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 66.56, with the RSI for the last a single of trading hit 74.39, and the three-weeks RSI is set at 60.73 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 2.27, while it was recorded at 2.46 for the last single week of trading, and 2.24 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: Deeper insight into the fundamentals
Return on Total Capital for ATOS is now -72.33, given the latest momentum, and Return on Invested Capital for the company is -88.40. Return on Equity for this stock declined to -88.42, with Return on Assets sitting at -62.18. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.07. Additionally, ATOS Total Debt to Total Capital is recorded at 0.07, with Total Debt to Total Assets ending up at 0.04.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,228,494 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Earnings analysis for Atossa Therapeutics Inc. [ATOS]
With the latest financial reports released by the company, Atossa Therapeutics Inc. posted -0.32/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
Insider trade positions for Atossa Therapeutics Inc. [ATOS]
There are presently around $8 million, or 7.60% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: BLACKROCK INC. with ownership of 1,532,282, which is approximately 228940.658% of the company’s market cap and around 0.04% of the total institutional ownership; VANGUARD GROUP INC, holding 518,109 shares of the stock with an approximate value of $1.22 million in ATOS stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $1.16 million in ATOS stock with ownership of nearly 561.654% of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 19 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 2,795,119 shares. Additionally, 13 investors decreased positions by around 237,649 shares, while 5 investors held positions by with 247,369 shares. The mentioned changes placed institutional holdings at 3,280,137 shares, according to the latest SEC report filing. ATOS stock had 12 new institutional investments in for a total of 417,227 shares, while 10 institutional investors sold positions of 103,819 shares during the same period.